{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:52:30Z","timestamp":1791204750134,"version":"4.2.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2024J01666"],"award-info":[{"award-number":["2024J01666"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018623","name":"Quanzhou City Science and Technology Program","doi-asserted-by":"publisher","award":["2024NY097"],"award-info":[{"award-number":["2024NY097"]}],"id":[{"id":"10.13039\/501100018623","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018623","name":"Quanzhou City Science and Technology Program","doi-asserted-by":"publisher","award":["2025QZNG002"],"award-info":[{"award-number":["2025QZNG002"]}],"id":[{"id":"10.13039\/501100018623","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bbadis.2026.168224","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:33:40Z","timestamp":1773419620000},"page":"168224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["ACE2 acts as a tumor suppressor in breast cancer by inhibiting progression via the TGF-\u03b21\/Smad pathway and potentiating immune checkpoint blockade"],"prefix":"10.1016","volume":"1872","author":[{"given":"Jianya","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feijing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangta","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbadis.2026.168224_bb0005","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.bbadis.2026.168224_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102198","article-title":"Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis","volume":"8","author":"Rizzo","year":"2023","journal-title":"ESMO open"},{"key":"10.1016\/j.bbadis.2026.168224_bb0015","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"BMJ (Clin. Res. ed.)"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168224_bb0020","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01805-y","article-title":"Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer","volume":"22","author":"Ye","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbadis.2026.168224_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110346","article-title":"Codelivery of triptolide and IFN-\u03b3 to boost antitumor immunity for triple-negative breast cancer","volume":"120","author":"Cai","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"8","key":"10.1016\/j.bbadis.2026.168224_bb0030","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","article-title":"Towards targeting the breast cancer immune microenvironment","volume":"24","author":"Harris","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.bbadis.2026.168224_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/biology13050352","article-title":"Associations between \u201cCancer risk\u201d, \u201cinflammation\u201d and \u201cmetabolic syndrome\u201d: a scoping review","volume":"13","author":"Vitale","year":"2024","journal-title":"Biology"},{"issue":"2","key":"10.1016\/j.bbadis.2026.168224_bb0040","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1158\/0008-5472.CAN-24-0954","article-title":"ACE2 enhances sensitivity to PD-L1 blockade by inhibiting macrophage-induced immunosuppression and angiogenesis","volume":"85","author":"Xie","year":"2025","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168224_bb0045","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12935-023-03080-9","article-title":"The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies","volume":"23","author":"Hassani","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"2","key":"10.1016\/j.bbadis.2026.168224_bb0050","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.canlet.2016.04.006","article-title":"Downregulation of ACE2\/Ang-(1-7)\/Mas axis promotes breast cancer metastasis by enhancing store-operated calcium entry","volume":"376","author":"Yu","year":"2016","journal-title":"Cancer Lett."},{"issue":"21","key":"10.1016\/j.bbadis.2026.168224_bb0055","doi-asserted-by":"crossref","first-page":"8319","DOI":"10.1158\/0008-5472.CAN-10-1136","article-title":"Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors","volume":"70","author":"Cook","year":"2010","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168224_bb0060","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13046-019-1156-5","article-title":"ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa\/VEGFR2\/ERK pathway","volume":"38","author":"Zhang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2026.168224_bb0065","article-title":"High expression of ACE2 in HER2 subtype of breast cancer is a marker of poor prognosis","volume":"27","author":"Nair","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168224_bb0070","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41598-021-03710-0","article-title":"Well-differentiated liver cancers reveal the potential link between ACE2 dysfunction and metabolic breakdown","volume":"12","author":"Desquilles","year":"2022","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.bbadis.2026.168224_bb0075","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.7150\/ijbs.81498","article-title":"ACE2 negatively regulates the Warburg effect and suppresses hepatocellular carcinoma progression via reducing ROS-HIF1\u03b1 activity","volume":"19","author":"Dong","year":"2023","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168224_bb0080","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bbrc.2015.02.030","article-title":"The association of renin-angiotensin system genes with the progression of hepatocellular carcinoma","volume":"459","author":"Ye","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"18","key":"10.1016\/j.bbadis.2026.168224_bb0085","doi-asserted-by":"crossref","first-page":"5289","DOI":"10.7150\/jca.49462","article-title":"Expression of the SAR2-Cov-2 receptor ACE2 reveals the susceptibility of COVID-19 in non-small cell lung cancer","volume":"11","author":"Zhang","year":"2020","journal-title":"J. Cancer"},{"issue":"3","key":"10.1016\/j.bbadis.2026.168224_bb0090","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3892\/or.2016.4967","article-title":"ACE2 overexpression inhibits acquired platinum resistance-induced tumor angiogenesis in NSCLC","volume":"36","author":"Cheng","year":"2016","journal-title":"Oncol. Rep."},{"issue":"W1","key":"10.1016\/j.bbadis.2026.168224_bb0095","doi-asserted-by":"crossref","first-page":"W534","DOI":"10.1093\/nar\/gkaf388","article-title":"TIMER3: an enhanced resource for tumor immune analysis","volume":"53","author":"Cui","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbadis.2026.168224_bb0100","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.clnesp.2025.03.023","article-title":"Prognostic significance of the cachexia index (CXI) in patients with cancer: a systematic review and meta-analysis","volume":"68","author":"Bas","year":"2025","journal-title":"Clin. Nutr. ESPEN"},{"issue":"16","key":"10.1016\/j.bbadis.2026.168224_bb0105","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf841","article-title":"SMAD3 and p300 complex scaffolding by long non-coding RNA LIMD1-AS1 promotes TGF-\u03b2-induced breast cancer cell plasticity","volume":"53","author":"Fan","year":"2025","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.bbadis.2026.168224_bb0110","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40291-023-00652-3","article-title":"Immune checkpoint blockade therapy for breast cancer: lessons from epithelial-mesenchymal transition","volume":"27","author":"O\u2019Connell","year":"2023","journal-title":"Mol. Diagn. Ther."},{"issue":"6","key":"10.1016\/j.bbadis.2026.168224_bb0115","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat. Med."},{"issue":"18","key":"10.1016\/j.bbadis.2026.168224_bb0120","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2217\/fon-2021-1647","article-title":"KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer","volume":"18","author":"Rizzo","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.bbadis.2026.168224_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102924","article-title":"Post-progression treatment options after CDK4\/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer","volume":"135","author":"Sahin","year":"2025","journal-title":"Cancer Treat. Rev."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443926000876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443926000876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:07:27Z","timestamp":1791202047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443926000876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0925443926000876"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2026.168224","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ACE2 acts as a tumor suppressor in breast cancer by inhibiting progression via the TGF-\u03b21\/Smad pathway and potentiating immune checkpoint blockade","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2026.168224","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"168224"}}